Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

Effect of different nutritional support on pancreatic secretion in acute pancreatitis [Vliianie raznykh sposobov nutritivnoĭ podderzhki na...

Ачкасов Е. Е., Пугаев А. В., Набиьева З. Г., Калачев С. В.
Хирургия. Журнал им. Н.И. Пирогова
Вып. 1, С. 14-20
Опубликовано: 2018
Тип ресурса: Статья

DOI:10.17116/hirurgia2018114-20

Аннотация:
AIM: To develop and justify optimal nutritional support in early phase of acute pancreatitis (AP).MATERIAL AND METHODS: 140 AP patients were enrolled. They were divided into groups depending on nutritional support: group I (n=70) - early enteral tube feeding (ETF) with balanced mixtures, group II (n=30) - early ETF with oligopeptide mixture, group III (n=40) - total parenteral nutrition (TPN). The subgroups were also isolated depending on medication: A - Octreotide, B - Quamatel, C - Octreotide + Quamatel. Pancreatic secretion was evaluated by using of course of disease, instrumental methods, APUD-system hormone levels (secretin, cholecystokinin, somatostatin, vasointestinal peptide).RESULTS: ETF was followed by pancreas enlargement despite ongoing therapy, while TPN led to gradual reduction of pancreatic size up to normal values. α-amylase level progressively decreased in all groups, however in patients who underwent ETF (I and II) mean values of the enzyme were significantly higher c
Ключевые слова:
acute pancreatitis; APUD-system hormones; cholecystokinin; enteral tube feeding; nutritional support; pancreas; pancreatic secretion; secretin; somatostatin; vasointestinal peptide
gastrointestinal agent; octreotide; oligopeptide; acute disease; drug effect; enteric feeding; female; human; male; middle aged; nutritional support; organ size; pancreas; pancreas function test; pancreatitis; pathology; pathophysiology; procedures; secretion (process); treatment outcome; Acute Disease; Enteral Nutrition; Female; Gastrointestinal Agents; Humans; Male; Middle Aged; Nutritional Support; Octreotide; Oligopeptides; Organ Size; Pancreas; Pancreatic Function Tests; Pancreatitis; Treatment Outcome
Язык текста: Русский
ISSN: 2309-5628
Ачкасов Е. Е. Евгений Евгеньевич 1974-
Пугаев А. В. Андрей Владимирович 1940-
Набиьева З. Г.
Калачев С. В. Сергей Валерьевич 1992-
Achkasov E. E. Evgenij Evgenyevich 1974-
Pugaev A. V. Andrej Vladimirovich 1940-
Nabiyeva Z. G.
Kalachev S. V. Sergej Valeryevich 1992-
Effect of different nutritional support on pancreatic secretion in acute pancreatitis [Vliianie raznykh sposobov nutritivnoĭ podderzhki na sekretsiiu zhelezy pri ostrom pankreatite]
Effect of different nutritional support on pancreatic secretion in acute pancreatitis [Vliianie raznykh sposobov nutritivnoĭ podderzhki na...
Текст визуальный непосредственный
Хирургия. Журнал им. Н.И. Пирогова
Издательство Медиа Сфера
Вып. 1 С. 14-20
2018
Статья
acute pancreatitis APUD-system hormones cholecystokinin enteral tube feeding nutritional support pancreas pancreatic secretion secretin somatostatin vasointestinal peptide
gastrointestinal agent octreotide oligopeptide acute disease drug effect enteric feeding female human male middle aged nutritional support organ size pancreas pancreas function test pancreatitis pathology pathophysiology procedures secretion (process) treatment outcome Acute Disease Enteral Nutrition Female Gastrointestinal Agents Humans Male Middle Aged Nutritional Support Octreotide Oligopeptides Organ Size Pancreas Pancreatic Function Tests Pancreatitis Treatment Outcome
AIM: To develop and justify optimal nutritional support in early phase of acute pancreatitis (AP).MATERIAL AND METHODS: 140 AP patients were enrolled. They were divided into groups depending on nutritional support: group I (n=70) - early enteral tube feeding (ETF) with balanced mixtures, group II (n=30) - early ETF with oligopeptide mixture, group III (n=40) - total parenteral nutrition (TPN). The subgroups were also isolated depending on medication: A - Octreotide, B - Quamatel, C - Octreotide + Quamatel. Pancreatic secretion was evaluated by using of course of disease, instrumental methods, APUD-system hormone levels (secretin, cholecystokinin, somatostatin, vasointestinal peptide).RESULTS: ETF was followed by pancreas enlargement despite ongoing therapy, while TPN led to gradual reduction of pancreatic size up to normal values. α-amylase level progressively decreased in all groups, however in patients who underwent ETF (I and II) mean values of the enzyme were significantly higher c